Sign up Australia
Proactive Investors - Run By Investors For Investors

Mayne Pharma Group considering a "significant transaction"

Mayne Pharma Group considering a "significant transaction"

Mayne Pharma Group (ASX: MYX) has been granted a trading halt this morning as it considers a "significant transaction", with the company's shares placed in pre-open.

Mayne Pharma has not yet indicated what the transaction might entail, but the company said in late September that it was reviewing a number of strategic options to grow the business - and is considering a capital raising as part of this strategy.

Currently Mayne Pharma develops and manufactures proprietary and generic products, which it distributes directly or through distribution partners, while also providing contract manufacturing services.

FY12 sales revenue grew 10% to $51.9 million, EBITDA grew 81% to $14.3 million, with the reported net profit after tax up 265% to $6.2 million. Net operating cash increased 228% to $13.4 million.

The halt will last until the earlier of an announcement being made to the market, or the opening of trade on Monday 8th October.

 

Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.





Register here to be notified of future MYX Company articles
View full MYX profile View Profile

Mayne Pharma Group Timeline

Related Articles

picture of drug research
August 23 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
shutterstock_244380844.jpg
April 21 2017
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use